Gastric hepatoid adenocarcinoma is a special type of gastric carcinoma, which produces AFP. We report a case of an metastatic gastric hepatoid adenocarcinoma mistaken for primary hepatocellular carcinoma (HCC). A 72 year-old woman was transferred to our hospital for treatment of the hepatic mass. She underwent subtotal gastrectomy for gastric cancer 2 years ago. A year ago, she was diagnosed with hepatic mass and treated with transhepatic chemoembolization under the suspicion of primary HCC in other hospital. The hepatic mass looked like primary HCC on CT, and serum AFP was elevated to 18,735 IU/mL. We did the transhepatic mass biopsy and compared it to the histology of the previous gastric cancer. The results of immunohistochemical staining between them was coincident, and so it was diagnosed as a hepatic metastasis of gastric hepatoid adenocarcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4166/kjg.2012.60.4.262 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hepatoid adenocarcinoma of the stomach with neuroendocrine differentiation: A case report.
Asian J Surg
December 2024
Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University(Henan Cancer Hospital), 127 Dongming Road, Zhengzhou City, Henan Province, 450008, China.
Conversion hepatectomy after chemotherapy including nivolumab for multiple liver metastases of hepatoid adenocarcinoma of the stomach: A case report and literature review.
Int J Surg Case Rep
December 2024
Department of Surgery, Onomichi General Hospital, 1-10-23 Hirahara, Onomichi, Hiroshima 722-8508, Japan.
Introduction: Currently, there is no evidence of the effectiveness of surgical intervention for Stage IV gastric cancer (GC); however, there are scattered reports of hepatectomy for liver metastasis of GC after chemotherapy including nivolumab.
Presentation Of Case: We report a case of a 79-year-old man with a history of laparoscopic distal gastrectomy with D2 lymph node dissection for GC, pathologically diagnosed as hepatoid adenocarcinoma of the stomach (HAS), with a combined positive score (CPS) for programmed death (PD)-ligand 1 was >5. Six months after gastrectomy, magnetic resonance imaging (MRI) showed multiple masses in both lobes of the liver, and the patient was treated with a regimen consisting of nivolumab and capecitabine with oxaliplatin (CapeOX).
Hepatoid adenocarcinoma of the stomach: discrimination from conventional gastric adenocarcinoma with a computed tomography-based radiomics nomogram.
J Gastrointest Oncol
October 2024
Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Background: Previous studies found it difficult to differentiate hepatoid adenocarcinoma of the stomach (HAS) from conventional gastric adenocarcinoma (CGA). We aimed to assess the efficacy of a computed tomography (CT)-based radiomics nomogram in identifying HAS.
Methods: Portal phase CT images were collected from 59 patients with HAS and 122 patients with CGA.
Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach.
Gastric Cancer
November 2024
Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-Ku, Fukuoka, 812-8582, Japan.
Background: Hepatoid adenocarcinoma of the stomach (HAS), a subtype of gastric cancer (GC), includes multiple tumor components, such as enteroblastic and tubular adenocarcinoma components. However, which component mostly contributes to the aggressive behavior of HAS remains unclear. Moreover, the role of tumor-associated macrophages (TAMs) has not been explored in HAS.
View Article and Find Full Text PDFA Case of Multisite Gastric Hepatoid Adenocarcinoma Mimicking Gastric Stromal Tumors.
Dig Dis Sci
November 2024
Department of Gastroenterology, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, Jiangsu, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!